Acquisition by Girin Pascal E R of 406 shares of Clearpoint Neuro at 15.38 subject to Rule 16b-3
| CLPT Stock | USD 15.89 0.35 2.25% |
Slightly above 55% of Clearpoint Neuro's private investors are presently thinking to get in. The analysis of overall sentiment of trading Clearpoint Neuro stock suggests that some investors are interested at this time. Clearpoint Neuro's investing sentiment can be driven by a variety of factors including economic data, Clearpoint Neuro's earnings reports, geopolitical events, and overall market trends.
Clearpoint |
Filed transaction by Clearpoint Neuro Director. Grant, award or other acquisition pursuant to Rule 16b-3(d)
Read at finance.yahoo.com
 |
Clearpoint Neuro Fundamental Analysis
We analyze Clearpoint Neuro's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clearpoint Neuro using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clearpoint Neuro based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Clearpoint Neuro is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Clearpoint Neuro Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Clearpoint Neuro stock to make a market-neutral strategy. Peer analysis of Clearpoint Neuro could also be used in its relative valuation, which is a method of valuing Clearpoint Neuro by comparing valuation metrics with similar companies.
Peers
Clearpoint Neuro Related Equities
| OM | Outset Medical | 19.66 | ||||
| APYX | Apyx Medical | 5.06 | ||||
| INSP | Inspire Medical | 5.02 | ||||
| INGN | Inogen | 4.68 | ||||
| RCEL | Avita Medical | 3.52 | ||||
| CTSO | Cytosorbents Crp | 2.17 | ||||
| KIDS | Orthopediatrics Corp | 2.10 | ||||
| ELMD | Electromed | 1.96 | ||||
| LIVN | LivaNova PLC | 1.33 | ||||
| TELA | Tela Bio | 1.04 | ||||
| LUNG | Pulmonx Corp | 0.46 | ||||
| TMCI | Treace Medical | 0.38 | ||||
| NPCE | Neuropace | 0.09 | ||||
| SRDX | SurModics | 0.40 | ||||
| SGHT | Sight Sciences | 2.51 | ||||
| NARI | Inari Medical | 3.92 |
Additional Tools for Clearpoint Stock Analysis
When running Clearpoint Neuro's price analysis, check to measure Clearpoint Neuro's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Clearpoint Neuro is operating at the current time. Most of Clearpoint Neuro's value examination focuses on studying past and present price action to predict the probability of Clearpoint Neuro's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Clearpoint Neuro's price. Additionally, you may evaluate how the addition of Clearpoint Neuro to your portfolios can decrease your overall portfolio volatility.